EE03016B1 - Peroraalselt manustatav ravimvorm tsentraalse dopamiinipuuduse-seisundi ravimiseks ja selle valmistamise meetod - Google Patents

Peroraalselt manustatav ravimvorm tsentraalse dopamiinipuuduse-seisundi ravimiseks ja selle valmistamise meetod

Info

Publication number
EE03016B1
EE03016B1 EE9400066A EE9400066A EE03016B1 EE 03016 B1 EE03016 B1 EE 03016B1 EE 9400066 A EE9400066 A EE 9400066A EE 9400066 A EE9400066 A EE 9400066A EE 03016 B1 EE03016 B1 EE 03016B1
Authority
EE
Estonia
Prior art keywords
weight
pct
parts
treatment
dopamine deficiency
Prior art date
Application number
EE9400066A
Other languages
English (en)
Estonian (et)
Inventor
Wenzel Udo
Weber G�nther
Metzner J�rgen
D�rr Alfred
Freitag Sabine
Fl�ther Frank-Ulrich
Albert Frank-Michael
Haase Margit
Leistner Edith
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of EE03016B1 publication Critical patent/EE03016B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EE9400066A 1991-01-23 1994-06-29 Peroraalselt manustatav ravimvorm tsentraalse dopamiinipuuduse-seisundi ravimiseks ja selle valmistamise meetod EE03016B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4101873A DE4101873C2 (de) 1991-01-23 1991-01-23 Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände

Publications (1)

Publication Number Publication Date
EE03016B1 true EE03016B1 (et) 1997-08-15

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400066A EE03016B1 (et) 1991-01-23 1994-06-29 Peroraalselt manustatav ravimvorm tsentraalse dopamiinipuuduse-seisundi ravimiseks ja selle valmistamise meetod

Country Status (22)

Country Link
US (1) US5532274A (xx)
EP (1) EP0568577B1 (xx)
JP (1) JP3382940B2 (xx)
AT (1) ATE147264T1 (xx)
AU (1) AU658171B2 (xx)
BG (1) BG61677B1 (xx)
CA (1) CA2101164C (xx)
CZ (1) CZ280847B6 (xx)
DE (2) DE4101873C2 (xx)
DK (1) DK0568577T3 (xx)
EE (1) EE03016B1 (xx)
ES (1) ES2098496T3 (xx)
FI (1) FI101040B (xx)
GR (1) GR3022993T3 (xx)
LT (1) LT3659B (xx)
LV (1) LV11103B (xx)
NO (1) NO304638B1 (xx)
RO (1) RO114737B1 (xx)
RU (1) RU2114619C1 (xx)
SK (1) SK369292A3 (xx)
UA (1) UA27848C2 (xx)
WO (1) WO1992012710A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
CN1596101A (zh) * 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 含有糖果组分的剂型
AU2003282603A1 (en) * 2002-10-11 2004-05-04 Depomed Development Ltd Gastro-retentive levodopa delivery form
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
RU2440100C2 (ru) * 2005-03-28 2012-01-20 Орексо Аб Новые фармацевтические композиции, полезные в лечении болезни паркинсона
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2009085306A1 (en) 2007-12-28 2009-07-09 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3054929B1 (en) 2013-10-07 2020-08-05 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP6695013B1 (ja) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 結合剤
CN112955136A (zh) * 2018-11-13 2021-06-11 日本瓦姆&珀巴尔株式会社 粘结剂
JP6694564B1 (ja) * 2018-11-13 2020-05-13 日本酢ビ・ポバール株式会社 結合剤
WO2020100932A1 (ja) * 2018-11-13 2020-05-22 日本酢ビ・ポバール株式会社 結合剤
JPWO2021205886A1 (xx) * 2020-04-10 2021-10-14
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (de) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Traegerstoff fuer Arzneimittel
DE748317C (de) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) * 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) * 1968-10-01 1976-05-17 Merck & Co Inc Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (de) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablette
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets
DE3875716D1 (de) * 1987-12-31 1992-12-10 Asta Medica Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets.

Also Published As

Publication number Publication date
EP0568577A1 (de) 1993-11-10
UA27848C2 (uk) 2000-10-16
NO932522L (no) 1993-07-09
RO114737B1 (ro) 1999-07-30
EP0568577B1 (de) 1997-01-08
FI933304A0 (fi) 1993-07-22
DE4101873A1 (de) 1992-07-30
LV11103B (en) 1996-06-20
FI933304A (fi) 1993-07-22
DK0568577T3 (da) 1997-06-30
GR3022993T3 (en) 1997-07-30
NO304638B1 (no) 1999-01-25
SK278736B6 (sk) 1998-02-04
DE59207852D1 (de) 1997-02-20
ATE147264T1 (de) 1997-01-15
CZ369292A3 (en) 1993-09-15
RU2114619C1 (ru) 1998-07-10
WO1992012710A1 (de) 1992-08-06
LT3659B (en) 1996-01-25
CA2101164C (fr) 2001-04-24
BG61677B1 (bg) 1998-03-31
JP3382940B2 (ja) 2003-03-04
NO932522D0 (no) 1993-07-09
BG97894A (bg) 1994-04-29
DE4101873C2 (de) 1993-12-09
AU658171B2 (en) 1995-04-06
LV11103A (lv) 1996-04-20
ES2098496T3 (es) 1997-05-01
CZ280847B6 (cs) 1996-04-17
FI101040B (fi) 1998-04-15
US5532274A (en) 1996-07-02
AU1186892A (en) 1992-08-27
JPH06504543A (ja) 1994-05-26
SK369292A3 (en) 1998-02-04
CA2101164A1 (fr) 1992-07-24
LTIP555A (en) 1994-11-25

Similar Documents

Publication Publication Date Title
EE03016B1 (et) Peroraalselt manustatav ravimvorm tsentraalse dopamiinipuuduse-seisundi ravimiseks ja selle valmistamise meetod
BG100933A (en) Polymer coated tablets comprising amoxycilin and clavulanate
AU3233795A (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
KR880000098A (ko) 콘드로이틴 설페이트 면역자극 조성물
HRP20030046B1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
IL117356A (en) Controlled release matrix and pharmaceutical compositions for oral administration containing it
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
YU47899B (sh) Postupak za dobivanje preparata koji sprečava prenošenje polnih bolesti i tampona koji ga sadrži
NO992944L (no) Virkestoffbµrer for avgivelse av apomorfin i munnhulen
CA2136404A1 (fr) Composition solide mucoadhesive, therapeutique ou hygienique, pour administration par application sur la muqueuse buccale ou nasale
EE04039B1 (et) Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
ATE315399T1 (de) Hemmung von systemischen infektionen in menschen und wirbeltieren mit ballaststoffen
FI955837A0 (fi) Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi
ES2139774T3 (es) Uso de una combinacion de antineoplastones en la preparacion de un medicamento para el tratamiento de la neurofibromatosis.
KR890007728A (ko) 진통제 제조방법
DK0615439T3 (da) Iburprofenholdigt retard-lægemiddel og dets anvendelse
DE60231997D1 (de) Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung
ATE86965T1 (de) Pharmazeutische kompositionen zum behandeln von adrenoleukodystrophie.
Farina et al. Antibacterial activity of Nicaraguan vegetal extracts used in folk medicine
RU2002112882A (ru) Способ повышения резистентности сухостойных коров
MX9705185A (es) Particula de resina, material medico y preparacion farmaceutica que contiene dicha particula de resina.
MX9605055A (es) Tableta revestida de polimero que comprende amoxicilina y clavulanato.
KR890002058A (ko) 간질 및 불안 상태의 예방 및 치료용 2,4,6-트리스-3-급-부틸아미노-1,-3,-5-트리아진

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

MM4A Lapsed by not paying the annual fees

Effective date: 20040629